company background image
LGDN logo

Ligand Pharmaceuticals DB:LGDN Stock Report

Last Price

€98.50

Market Cap

€1.9b

7D

-7.9%

1Y

50.4%

Updated

14 Mar, 2025

Data

Company Financials +

Ligand Pharmaceuticals Incorporated

DB:LGDN Stock Report

Market Cap: €1.9b

LGDN Stock Overview

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. More details

LGDN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Ligand Pharmaceuticals Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ligand Pharmaceuticals
Historical stock prices
Current Share PriceUS$98.50
52 Week HighUS$120.00
52 Week LowUS$63.50
Beta1.03
1 Month Change-7.08%
3 Month Change-8.80%
1 Year Change50.38%
3 Year Change0.86%
5 Year Change26.28%
Change since IPO18.50%

Recent News & Updates

Recent updates

Shareholder Returns

LGDNDE PharmaceuticalsDE Market
7D-7.9%-5.6%-3.5%
1Y50.4%-14.5%13.6%

Return vs Industry: LGDN exceeded the German Pharmaceuticals industry which returned -14.5% over the past year.

Return vs Market: LGDN exceeded the German Market which returned 13.6% over the past year.

Price Volatility

Is LGDN's price volatile compared to industry and market?
LGDN volatility
LGDN Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement4.4%
Market Average Movement5.4%
10% most volatile stocks in DE Market11.9%
10% least volatile stocks in DE Market2.7%

Stable Share Price: LGDN has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: LGDN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198768Todd Daviswww.ligand.com

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.

Ligand Pharmaceuticals Incorporated Fundamentals Summary

How do Ligand Pharmaceuticals's earnings and revenue compare to its market cap?
LGDN fundamental statistics
Market cap€1.87b
Earnings (TTM)-€3.71m
Revenue (TTM)€153.58m

12.2x

P/S Ratio

-507.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LGDN income statement (TTM)
RevenueUS$167.13m
Cost of RevenueUS$32.50m
Gross ProfitUS$134.63m
Other ExpensesUS$138.67m
Earnings-US$4.03m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin80.55%
Net Profit Margin-2.41%
Debt/Equity Ratio0%

How did LGDN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 00:55
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ligand Pharmaceuticals Incorporated is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Balaji PrasadBarclays